Author:
Sommefleck Fernando A.,Schneeberger Emilce E.,Citera Gustavo
Reference79 articles.
1. Appel, H., & Sieper, J. (2008). Spondyloarthritis and the crossroads of imaging, pathology, and structural damage in the era of biologics. Current Rheumatology Reports, 10, 356–363.
2. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB. (2015 Dec 24) MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med, 373(26):2534-48.
3. Bergfeldt, L., Edhag, O., Vedin, L., & Vallin, H. (1982). Ankylosing spondylitis: An important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. American Journal of Medicine, 73(2), 187–191.
4. Boyer, G. S., Lanier, A. P., & Templin, D. W. (1988). Prevalence rates of spondyloarthropathies, rheumatoid arthritis, and other rheumatic disorders in an Alaskan Inupiat Eskimo population. Journal of Rheumatology, 15(4), 678–683.
5. Brandt, J., Listing, J., Sieper, J., et al. (2004). Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases, 63(11), 1438–1444.